Dogwood Therapeutics (DWTX) Registration Filing summary

Company overview and business model

• Operates as a pre-revenue, development-stage biopharmaceutical company focused on pain and fatigue-related disorders, with programs in Nav1.7 modulation for pain and combination antiviral therapies for herpes virus-mediated illnesses.

• Lead candidate Halneuron® targets chronic and acute pain, with a Phase 2b study initiated in Q1 2025; antiviral pipeline includes IMC-1 and IMC-2 for fibromyalgia and Long-COVID.

• Underwent several corporate changes, including a business combination with Pharmagesic and a name change to Dogwood Therapeutics in October 2024.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were approximately $6.5 million, with Q4 2025 operating expenses around $3.9 million, consistent with projections.

• Terminated an $8.56 million ATM equity program in January 2026 after raising $89,792.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds go directly to selling stockholders.

• Responsible for certain offering fees and expenses related to registration.